Neurogene

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
  TipRanks · 2026/6/11
• Rating change
  Guggenheim Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $69
  Market Newswire · 2026/4/28
• Rating change
  William Blair Maintains Neurogene(NGNE.US) With Buy Rating
  Market Newswire · 2026/6/8
• Rating change
  Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating
  Market Newswire · 2026/4/21
• Rating change
  Guggenheim Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $69
  Market Newswire · 2026/6/30
• Rating change
  CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $180
  Market Newswire · 2026/5/13
• Rating change
  LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/4/17
• Rating change
  H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65
  Market Newswire · 2026/8/13
• Rating change
  Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65
  Market Newswire · 2026/5/15
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/7/11
• A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180
  Market Newswire · 2026/6/30
• Rating change
  CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $166
  Market Newswire · 2026/8/13
• Rating change
  Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
  Market Newswire · 2026/8/14
• Rating change
  LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $60
  Market Newswire · 2026/5/13
• Rating change
  TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
  Market Newswire · 2026/5/13
• A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166
  Market Newswire · 2026/8/12
• Rating change
  Rodman & Renshaw Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $70
  Market Newswire · 2026/6/3
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2026/6/23
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65
  Market Newswire · 2026/7/8
• Rating change
  H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70
  Market Newswire · 2026/6/9

Headlines are aggregated automatically and are not independently verified or edited by our team.